More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$28.05B
EPS
-0.57
P/E ratio
--
Price to sales
3398.72
Dividend yield
--
Beta
1.232417
Previous close
$38.61
Today's open
$38.38
Day's range
$37.38 - $38.74
52 week range
$19.96 - $42.50
show more
CEO
Matthew Gline
Employees
721
Headquarters
London,
Exchange
Nasdaq Global Select
Shares outstanding
724561460
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
Roivant Sciences Ltd. (ROIV) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Roivant Sciences Ltd. (ROIV) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Seeking Alpha • Nov 17, 2026

Don't Fight The Momentum: Roivant Has Big Expectations, But Real Pipeline Momentum
Roivant Sciences Ltd. remains a Buy as its diversified "-vant" model delivers multiple blockbuster pipeline opportunities and robust cash reserves. Immunovant's IMVT-1402 shows superior efficacy in rheumatoid arthritis, but regulatory and translational hurdles remain for broader adoption. Priovant's LISRAYA launches in dermatomyositis, with promising Phase 3 data in non-infectious uveitis, while Pulmovant's mosliciguat demonstrates best-in-class Phase 2 results in PH-ILD.
Seeking Alpha • Nov 11, 2026

Priovant Announces Publication of Phase 2 BEACON Results for Brepocitinib in Cutaneous Sarcoidosis in JAMA Dermatology
DURHAM, N.C., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Priovant Therapeutics today announced the publication in JAMA Dermatology of results from the Phase 2 portion of the BEACON study, a randomized, double-blind, placebo-controlled trial evaluating oral brepocitinib in adults with cutaneous sarcoidosis (CS). The publication describes improvements in skin disease activity and skin-related quality of life over 16 weeks of treatment, with 69.2% of participants receiving brepocitinib 45 mg once daily achieving “Clear” or “Almost Clear” skin with at least a 2-category improvement, compared with none of the participants receiving placebo (P = 0.0047).
GlobeNewsWire • Nov 10, 2026

Roivant Sciences Q2 Earnings Call Highlights
Roivant Sciences NASDAQ: ROIV reported $31 million in net revenue from the initial launch of LISRAYA and said an experimental rheumatoid arthritis treatment met its primary endpoint in a randomized withdrawal study.
MarketBeat • Nov 9, 2026

Roivant Sciences Ltd. (ROIV) Q2 2026 Earnings Call Transcript
Roivant Sciences Ltd. ( ROIV ) Q2 2026 Earnings Call November 9, 2026 8:00 AM EST Company Participants Stephanie Lee Griffin - Chief Operating Officer of Roivant Platforms Matthew Gline - CEO & Director Conference Call Participants David Risinger - Leerink Partners LLC, Research Division Samuel Slutsky - LifeSci Capital, LLC, Research Division Yaron Werber - TD Cowen, Research Division Thomas Smith - Leerink Partners LLC, Research Division Yuchen Ding - Jefferies LLC, Research Division Lut Ming Cheng - JPMorgan Chase & Co, Research Division Patrick Culliton - Stifel, Nicolaus & Company, Incorporated, Research Division Yasmeen Rahimi - Piper Sandler & Co., Research Division Jacob Goell - Wells Fargo Securities, LLC, Research Division Samantha Semenkow - Citigroup Inc., Research Division Douglas Tsao - H.C.
Seeking Alpha • Nov 9, 2026

Roivant Reports Financial Results for the Second Quarter Ended September 30, 2026, and Provides Business Update
LISRAYA™ (brepocitinib) generated net product revenue of $31.0 million in its first 5 weeks of launch following FDA approval in August 2026 IMVT-1402 600 mg met the primary endpoint of ACR20 response at Week 28 (92.5% vs. 75.6% placebo, p=0.0139) in Period 2 (randomized withdrawal design following open-label lead-in) of the potentially registrational trial in patients with difficult-to-treat rheumatoid arthritis (D2T RA); FDA discussions planned for later this year to determine the path forward regarding the registrational program for IMVT-1402 in D2T RA Brepocitinib met the primary and all key secondary endpoints in the Phase 3 CLARITY-1 and CLARITY-2 trials in non-infectious uveitis (NIU); sNDA submission for NIU expected in the first half of calendar year 2027 Mosliciguat demonstrated positive topline data in the Phase 2 PHocus study in pulmonary hypertension associated with interstitial lung disease (PH-ILD); Phase 3 PHrontier study initiated In light of the evolving Sjögren's disease (SjD) landscape and recent data in the field, we expect it is unlikely that we will advance IMVT-1402 further in SjD beyond the ongoing, fully enrolled Phase 2 trial Roivant reported consolidated cash, cash equivalents and marketable securities of $4.2 billion as of September 30, 2026, including the cash payment received from Moderna in July, supporting cash runway into profitability Roivant will host a live conference call and webcast at 8:00 a.m.
GlobeNewsWire • Nov 9, 2026

Roivant Sciences Ltd. (ROIV) Reports Q2 Loss, Tops Revenue Estimates
Roivant Sciences Ltd. (ROIV) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.41.
Zacks Investment Research • Nov 9, 2026

Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended September 30, 2026
IMVT-1402 600 mg met the primary endpoint of ACR20 response at Week 28 (92.5% vs. 75.6% placebo, p=0.0139) in Period 2 (randomized withdrawal design following open-label lead-in) of the potentially registrational trial in patients with difficult-to-treat rheumatoid arthritis (D2T RA) In exploratory analyses, ACR50 and ACR70 response rates for patients who remained on IMVT-1402 600 mg in Period 2 continued to increase, reaching 80.0% ACR50 and 52.5% ACR70 at Week 28 FDA discussions planned for later this year to determine the path forward regarding the registrational program for IMVT-1402 in D2T RA In light of the evolving Sjögren's disease (SjD) landscape and recent data in the field, we expect it is unlikely that we will advance IMVT-1402 further in SjD beyond the ongoing, fully enrolled Phase 2 trial All other clinical development timelines remain on track Roivant will host a live conference call and webcast at 8:00 a.m.
GlobeNewsWire • Nov 9, 2026

Roivant Sciences' Brepocitinib Delivers Positive Phase III Uveitis Results
Roivant Sciences NASDAQ: ROIV reported positive Phase III results from its CLARITY-1 and CLARITY-2 studies evaluating brepocitinib, which the company referred to as Brepo, in noninfectious uveitis (NIU), an inflammatory eye disease that can result in vision loss.
MarketBeat • Oct 21, 2026

Roivant to Report Financial Results for the Second Quarter Ended September 30, 2026, and Provide Business Update on Monday, November 9, 2026
BASEL, Switzerland and LONDON and NEW YORK, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Monday, November 9, 2026, to report its financial results for the second quarter ended September 30, 2026, and provide a business update.
GlobeNewsWire • Oct 21, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Roivant Sciences Ltd. commission-free¹. Build wealth for the long term using automated trading and transfers.